Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
Boehringer Ingelheim
Harvard Business School
Colorcon
Dow
Medtronic

Last Updated: January 25, 2020

DrugPatentWatch Database Preview

ORENCIA Drug Profile

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Recent Clinical Trials for ORENCIA

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Stuart Knechtle, M.D.Phase 1
Carla Greenbaum, MDEarly Phase 1
Juvenile Diabetes Research FoundationEarly Phase 1

See all ORENCIA clinical trials

Recent Litigation for ORENCIA

Identify key patents and potential future biosimilar entrants

District Court Litigation
Case NameDate
Celgene Corporation v. Aurobindo Pharma Limited2018-07-06
CELGENE CORPORATION v. EMCURE PHARMACEUTICALS LTD.2018-06-28
CELGENE CORPORATION v. SANDOZ INC.2018-06-26

See all ORENCIA litigation

PTAB Litigation
PetitionerDate
Crescendo Bioscience, Inc2017-04-12

See all ORENCIA litigation

Pharmacology for ORENCIA
Ingredient-typeRecombinant Fusion Proteins
Physiological EffectDecreased Cytokine Activity

Patent Text Search: US Patents for ORENCIA

These patents were identified by searching patent claims

Supplementary Protection Certificates for ORENCIA

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
17C1057 France   Start Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170627
15C0029 France   Start Trial PRODUCT NAME: IBRUTINIB OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI; REGISTRATION NO/DATE: EU/1/14/945 20141023
2015/020 Ireland   Start Trial PRODUCT NAME: IBRUTINIB, OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; REGISTRATION NO/DATE: EU/1/14/945 20141021
122016000093 Germany   Start Trial PRODUCT NAME: LBRUTINIB ODER EIN PHARMAZEUTISCH ANNEHMBARES SALZ DAVON; REGISTRATION NO/DATE: EU/1/14/945 20160526
C300728 Netherlands   Start Trial PRODUCT NAME: IBRUTINIB OF EEN FARMACEUTISCH AANVAARDBAAR ZOUT ERVAN; REGISTRATION NO/DATE: EU/1/14/945 20141021
CA 2017 00012 Denmark   Start Trial PRODUCT NAME: IBRUTINIB, ELLER ET FARMACEUTISK ACCEPTABELT SALT DERAF; REG. NO/DATE: EU/1/14/945 C(2015)4704 20150707
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Express Scripts
McKinsey
McKesson
Dow
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.